Exercise of options

RNS Number : 7037T

Synairgen plc

08 October 2014

 



PRESS RELEASE

8 October 2014

SYNAIRGEN PLC

("Synairgen" or "the Company")

Exercise of options

Southampton, UK, 8 October 2014: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has applied for 4,712 ordinary shares of one pence each (the "Option Shares") to be admitted to trading on the AIM Market of the London Stock Exchange ("AIM") ("Admission"). It is expected that Admission will occur and that dealings will commence in the Option Shares on 13 October 2014.

The Options Shares are being issued pursuant to the exercise of options by a former employee of the Company. The Options Shares will rank pari passu with the Company's existing ordinary shares.

Following Admission, the number of Ordinary Shares in issue and admitted to trading on AIM will be 91,175,084.

ENDS

For further information, please contact:

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Christopher Raggett (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com 

 

END

 

 

POSQKODBABDDDKK